Defining the Decline in Endogenous Insulin Secretion in Type 1 Diabetes Diagnosed After 30 Years of Age.

Launched by ROYAL DEVON AND EXETER NHS FOUNDATION TRUST · Dec 22, 2020

Keywords

ClinConnect Summary

The study aims to evaluate progression of type 1 diabetes. Primary analysis will be conducted on those with \>=1 diabetes autoantibody positive (GAD, IA2 ZNT8). Sensitivity analysis will be performed by repeating all analysis defining T1D as a) double antibody positivity and b) single antibody positivity combined with a high genetic risk score for T1D (T1DGRS\>5th centile of a control population).

Further aims will be to evaluate the utility of dried blood spot testing to detect change in C-peptide and the utility of home test results as a marker of hypoglycaemia and glucose variability.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults with a clinical diagnosis of Type 1 diabetes within the previous 100 days.
• • Aged \>30 at the time of Type 1 diabetes diagnosis OR (additional early onset Type 1 diabetes cohort) aged ≥18 and ≤30 at the time of Type 1 diabetes diagnosis.
• • Insulin treated at the time of recruitment
• • Able and willing to provide informed consent.
• • Exclusion criteria
• • Pregnancy
• • Known monogenic diabetes
• • Known secondary diabetes (diabetes considered likely due to medication, cystic fibrosis, pancreatitis, pancreatic cancer, pancreatic surgery, hemochromatosis or Cushing's syndrome).